Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Research & Development (2019 - 2025)

Eton Pharmaceuticals' Research & Development history spans 7 years, with the latest figure at $1.1 million for Q3 2025.

  • For Q3 2025, Research & Development rose 120.2% year-over-year to $1.1 million; the TTM value through Sep 2025 reached $5.1 million, down 1.14%, while the annual FY2024 figure was $3.3 million, 2.02% down from the prior year.
  • Research & Development for Q3 2025 was $1.1 million at Eton Pharmaceuticals, down from $3.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $3.7 million in Q2 2025 and bottomed at -$871000.0 in Q4 2024.
  • The 5-year median for Research & Development is $886000.0 (2021), against an average of $1.1 million.
  • The largest YoY upside for Research & Development was 164.0% in 2024 against a maximum downside of 183.19% in 2024.
  • A 5-year view of Research & Development shows it stood at $681000.0 in 2021, then soared by 38.62% to $944000.0 in 2022, then rose by 10.91% to $1.0 million in 2023, then tumbled by 183.19% to -$871000.0 in 2024, then surged by 227.67% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Research & Development are $1.1 million (Q3 2025), $3.7 million (Q2 2025), and $1.2 million (Q1 2025).